Large-scale cancer genomic studies enable the systematic identification of mutations that lead to the genesis and progression of tumors, uncovering the underlying molecular mechanisms and potential therapies. While some such mutations are recurrently found in many tumors, many others exist solely within a few samples, precluding detection by conventional recurrence-based statistical approaches. Integrated analysis of somatic mutations and RNA expression data across 12 tumor types reveals that mutations of cancer genes are usually accompanied by substantial changes in expression. We use topological data analysis to leverage this observation and uncover 38 elusive candidate cancerassociated genes, including inactivating mutations of the metalloproteinase ADAMTS12 in lung adenocarcinoma. We show that ADAMTS12 -/mice have a five-fold increase in the susceptibility to develop lung tumors, confirming the role of ADAMTS12 as a tumor suppressor gene. Our results demonstrate that data integration through topological techniques can increase our ability to identify previously unreported cancer-related alterations.
Introduction
A critical foundation for targeted cancer therapies is the identification of molecular mechanisms that are necessary for tumor development and maintenance. Large-scale crosssectional cancer molecular studies, such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium, enable this identification by systematically compiling genetic alterations across many tumors 1,2 . Tumors that present recurrently altered genes or pathways are suspected to be driven by common molecular mechanisms.
By leveraging computational approaches that seek signatures of positive selection 3 , these studies have produced extensive catalogues of frequently-mutated, cancer-associated genes 4 . These studies have also revealed that most cancer mutations occur at low frequencies (< 10% of samples), including potentially actionable therapeutic targets 4 .
The identification of low-prevalence cancer-associated mutations using recurrence-based methods is challenging because of the large number of samples needed to achieve statistical power and the inherent complexity in modeling the background mutation rates. The rate of neutral mutations within a cancer type can dramatically differ among patients, genomic regions, or mutation types 3 , limiting the power of recurrence-based methods. It is estimated that for the current size of ongoing cross-sectional studies (typically consisting of less than 1,000 patients) only cancer-associated mutations that occur at intermediate or high frequencies (> 15%) are fully accessible to recurrence-based methods 4 . This is consistent with the observation that patients in these studies often completely lack mutations in known cancer-associated genes 5 . These results highlight the need of recurrence-based methods that can model rare events 6, 7 or, alternatively, methods for the identification of cancerassociated genes that are not based on recurrence.
An approach to the identification of cancer-associated genes that is not based on modeling the mutation rate is the integration of other types of data from the tumor 8, 9 . If a mutation is accompanied by consistent changes in copy number, gene expression, and/or methylation, it is possible to leverage these changes to relate the mutation event to cancer progression.
Several studies have utilized changes in the copy number, expression, or methylation of the mutated gene (cis-effects) to identify novel cancer-associated mutations [10] [11] [12] . However, the identification of cancer-associated mutations based on changes in genes other than the mutated gene (trans-effects) is more challenging and usually requires providing information about known gene-gene relationships to reduce the number of false positives. DriverNet 13 , OncoIMPACT 14 , CaMoDi 15 , and Xseq 16 utilize trans-effects in gene expression to identify cancer-associated mutations. To limit the dimensionality of the expression space, these methods use expression modules (sets of co-expressed genes, functionally related genes, or gene networks). However, an approach that fully takes into account the complexity of the expression space is currently lacking.
Current approaches for the identification of cancer-associated mutations using expression data are sensitive to several confounding effects. Genomic regions with open chromatin can be more easily accessed by DNA repair enzymes, leading to anti-correlations between gene expression levels and mutation rates 3 . Furthermore, tumors with different expression signatures, such as genomically unstable tumors, can have different mutation rates 17, 18 .
These effects lead to spurious correlations between mutations and expression signatures and are a source of false positives for current algorithms.
To address these problems, we have devised an approach to identify cancer-associated mutated genes using expression data from multiple tumors. Our approach makes use of topological data analysis 19, 20 (TDA) to reconstruct the structure of the expression space, and takes into account the above spurious effects when assessing the significance of a mutated gene. Its application to mutation and expression data of 4,476 patients from 12 tumor types leads to the identification of 95 mutated cancer genes, out of which 38 are previously unreported low-prevalence genes (average prevalence within the same tumor cohort = 5%) . We hence propose a complementary approach to recurrence-based methods, enabling the identification of elusive, but potentially clinically-relevant, mutated cancer genes.
Results

Topological reconstruction of the expression space of low grade gliomas
The expression profile of a tumor can be mathematically described as a point in a highdimensional expression space, where each dimension represents the mRNA level of a gene and the dimensionality of the space is given by the number of expressed genes. Points that lie close to each other in this space correspond to tumors with similar expression profiles.
The set of all possible tumors of a cancer type spans a sub-space of the expression space.
Measuring the expression profiles of individual tumors in a cross-sectional study is equivalent to sampling a finite set of points from this sub-space.
We considered 513 primary low grade glioma (LGG) tumors from TCGA for which both RNA-seq and whole-exome DNA-seq data were available 21 . To infer the structure of the expression space of LGG from this RNA-seq data, we used a topological approach 19, 20 .
Topology is the mathematical field that studies how different parts of a space are connected to each other. TDA generalizes some of the notions of topology to sets of points and pairwise distances. Thus, TDA aims to infer and summarize the topological structure of a space given only a finite sample of points. TDA has been recently used to study viral reassortment 22 , human recombination 23, 24 , cell differentiation 25 , breast cancer 26 , and other complex genetic diseases 27 .
We used the TDA algorithm Mapper 28 to build a low-dimensional representation of the expression space of LGG using the expression data of the TCGA cohort ( Fig. 1a ). Mapper generates a network representation of the expression space, in which each node corresponds to a set of tumors with similar expression profile. A given tumor can appear in more than one node, and if two nodes have one or more tumors in common they are connected by an edge. Contrary to other methods for dimensionality reduction, such as principal component analysis and multi-dimensional scaling 29 , the topological representations produced by Mapper preserve local relationships of the high-dimensional expression space. Any two tumors close to each other in the topological representation (as measured by the number of edges contained in the shortest path that connects the two tumors) are ensured to be close to each other in the original high-dimensional expression space. We used Pearson's correlation as a measure of similarity between the expression profiles of individual tumors. The topological representation of the LGG expression space consisted of three regions ( Fig. 1a) , consistent with the expression sub-types found in clustering analyses 21 . These regions, however, were bridged by thin structures in the topological representation, indicating that some tumors have an expression profile characteristic of multiple expression sub-types ( Fig. 1a ).
Identification of cancer-associated mutated genes in LGG
We hypothesized that if a mutated gene appears localized in the expression space, it is associated with consistent global expression patterns across a subset of tumors, and is therefore a candidate driver of tumor progression ( Fig. 1b ). On the other hand, if mutations of a gene are clonally expanded as a result of being in the same genome as a positivelyselected mutation, but are not cancer-related, they will appear randomly scattered in the expression sub-space ( Fig. 1b ).
To test this hypothesis, we implemented a computational approach that assesses the localization of non-synonymous somatic mutations in the expression space of tumors (Methods). To control for the presence of spurious correlations between the mutation rate and the tumor expression profile, we assessed the localization of the mutational tumor burden (defined as the total number of somatic mutations in each tumor) in the reconstructed expression space ( Supplementary Fig. 1a , Methods). Based on this analysis, we sub-sampled mutations in two hyper-mutated tumors (nmut > 10 2.5 ) that were present in the LGG cohort. In addition, we assessed the similarity between the expression and the mutation profile of each individual gene in the reconstructed expression space (Methods).
After correcting for these spurious correlations, 16 mutated genes were significantly localized in the reconstructed expression space of LGG ( Fig. 1c , q-value < 0.15, Benjamini-Hochberg procedure). These included well-known high-prevalence (> 15%) driver genes, like IDH1, TP53, ATRX, and CIC, in addition to several low-prevalence mutated genes, like NIPBL (mutated in 4% of the tumors) and ZNF292 (mutated in 3% of the tumors), which have been recently reported in a larger cohort of gliomas 21 . In total, 15 out of the 16 significant mutated genes were previously reported 21, 30 , with SYNE1 (mutated in 2% of the tumors) the only new candidate. We did not observe a significant correlation between the significance and prevalence of statistically significant genes (Pearson's correlation coefficient between prevalence and q-value, r = -0.34, p-value = 0.19). In particular, some of the most significant genes according to our approach, like FUBP1, NOTCH1, PTEN, EGFR, and NF1, were mutated in less than 10% of the patients within that tumor type ( Fig.   1c ), indicating that mutations in these genes are strongly associated with global changes in expression. These results were stable across the parameter space of the Mapper algorithm ( Fig. 1c , Supplementary Fig. 1b , Methods).
The location of significant genes in the reconstructed expression space of LGG was consistent with the known molecular subtypes of adult diffuse gliomas 21 (Fig. 1d , Supplementary Fig. 2 ). Of particular note, IDH2-mutant tumors were localized within the expression space of oligodendrogliomas, indicating a distinct expression profile from that of IDH1-mutant oligodendrogliomas ( Fig. 1d , Supplementary Fig. 2a ). This observation is consistent with a recent study based on genomic variations 31 .
Neuronal marker expression has been reported in malignant (grade III/IV) gliomas other than classical anaplastic gangliogliomas 32, 33 . In our cohort, tumors expressing canonical neuronal markers like neurofilament (NEFL, NEFM, and NEFH) and synaptophysin (SYP) were significantly localized within the expression space of oligodendrogliomas (q-value < 0.015, Supplementary Fig. 3 ). These tumors harbored frequent deletions of the chromosome arm 19q, in addition to molecular alterations characteristic of astrocytic gliomas, such as TP53 and ATRX mutations (Fisher's exact test p-value < 0.01, Supplementary Fig. 3 ). Although the average estimated tumor purity 34 in this group was significantly lower than for the rest of the oligodendroglioma expression group (Mann-Whitney U-test p-value = 0.001, average estimated tumor purities = 92% and 96%, respectively), the estimated tumor content was in many cases (n = 7) above 98%, suggesting that the expression of neuronal markers is not due to a poor tumor purity.
Computational benchmarking
To assess the number cancer-associated genes identified by our approach as a function of the size of the cohort, we repeated the same analysis in smaller cohorts generated by randomly sampling patients from the original LGG cohort (Fig 1e) . We also assessed the number of false positives by generating randomized datasets, where we permuted the labels of the patients in the expression data. We observed that our approach requires a minimum cohort size of approximately 100 tumors. For larger cohorts, the expected number of false positives was between 1 and 2 ( Fig. 1e ).
Next, we sought to compare our results against current algorithms for the identification of cancer-associated genes using expression data. To that end, we analyzed the same LGG cohort using the recently published algorithm Xseq 16 (Methods). Xseq implements a hierarchical Bayes statistical model to quantify the impact of somatic mutations on expression profiles using a pre-computed 'influence graph' that encodes whether two genes are known to be functionally related. The analysis of the LGG cohort with Xseq led to only 2 significant genes (posterior probability, P(D) > 0.80), of which only one (PTEN) has been previously reported in LGG. These results reveal the high sensitivity of our topological approach compared to state-of-the-art algorithms.
In addition to Xseq, we compared the results of our integrative topological approach to those produced by MutSig2CV on the same cohort ( Fig. 1f ). MutSig2CV models the neutral background mutation rate, taking into account genomic variations due to differences in expression level and replication time 3 . We observed a significant overlap between the results of MutSig2CV and those of our approach, with 15 out of 23 mutated genes that were significant (q-value < 0.15) according to MutSig2CV, being also significant according to our approach (65% overlap, Fisher's exact test p-value = 10 -42 ).
Some of the most significant cancer genes identified by MutSig2CV based on recurrence, such as PIK3R1 (mutated in 4% of the tumors), were not selected by our expression-based approach, highlighting the independence of recurrence-and expression-based approaches.
Combining the results of MutSig2CV with those of our integrative topological approach Seeking a more systematic comparison with existing methods, we performed a similar study to that of Bertrand et al. 35 across multiple tumor types (Methods). We estimated the precision, recall, and F1 score of our integrative topological approach, Xseq, MutSig2CV, OncodriveFML 36 , and 20/20+ 37 based on the overlap of their top 15 predictions with a gold-standard list of cancer-associated genes 35 . In addition to the LGG cohort, we analyzed two cohorts of 208 colorectal adenocarcinoma (COAD) and 930 breast invasive carcinoma (BRCA) tumors from TCGA, respectively. In each of the three cohorts, the precision, recall, and F1 score of our integrative topological approach were the highest or second highest among the 5 algorithms ( Supplementary Table 1 ), highlighting its utility for the identification of mutated cancer-associated genes.
Identification of cancer-associated genes across 12 tumor types
Based on the above results, we decided to extend our analysis to other tumor types. We considered 12 tumor types from TCGA for which there were sufficient samples (n > 140) with RNA-seq and whole-exome data available (Table 1 ). The complete results of our analysis can be accessed through an online database (Methods). In total, our approach identified 95 mutated cancer genes (q-value < 0.15), out of which 16 genes were significant in two or more tumor types ( Fig. 2a Table   2 ). Some of the most common genes were TP53, KRAS, HRAS, PIK3CA, ATRX, EGFR, and NF1. The number of significant genes in each tumor type was correlated with the size of the cohort (Fig. 2b , Spearman's correlation coefficient r = 0.67, p-value = 0.02), consistently with the results of the computational benchmarking. We observed a large degree of consistency between the list of significant genes and curated databases of cancer genes. Specifically, 61% of the significant genes in our analysis were present in the Cancer Gene Census 38 or OncoKB 39 databases ( Fig. 2c , Fisher's exact test p-value < 10 -50 for each database). Overall, 75% of the patients carried a mutation in a significant gene, out of which 24% carried mutations in actionable genes with approved drugs 35 ( Supplementary Table   3 ).
The results were largely consistent with those of MutSig2CV on the same TCGA cohorts ( Fig. 2a, Supplementary Fig. 16 , and Table 1 ), adding further support to some of the cancer genes identified in our analysis. Out of the 95 significant genes in the integrative topological analysis, 38 genes were not significant according to MutSig2CV (Fig. 2a , qvalue < 0.15). However, these putative elusive cancer genes did often displayed a tendency towards significance in the MutSig2CV analysis, likely reflecting a limitation of the cohort size ( Supplementary Fig. 16 ). They also had a significant overlap with the Cancer Gene Census (8 out of 38 genes, Fisher's exact test p-value = 2·10 -5 , Fig. 2d ) and OncoKB (6 out of 38 genes, Fisher's exact test p-value = 3·10 -4 , Fig. 2d ) databases, as well as with genes involved in developmental processes (27 out of 38 genes, g:SCS q-value = 10 -3 ).
Elusive genes included NOTCH2 mutations in breast invasive carcinoma (mutated in 2% of the tumors), which have been recently reported by manual inspection 40 ; inactivating mutations of the tumor-suppressor genes KMT2A 41 (also known as MLL1) and CUX1 42 in head and neck squamous cell carcinoma (each present in 1% of the tumors); inactivating mutations of the tumor-suppressor gene ADAMTS12 43 in lung adenocarcinoma (present in 4% of the tumors); mutations in the kinase domain of CHEK2 in thyroid carcinoma (present in 1% of the tumors), which have been associated with increased susceptibility to this cancer type 44 ; inactivating mutations of the putative tumor-suppressor gene USP9X in thyroid carcinoma (present in 1% of the tumors), which codes for a deubiquitinase regulating the TGF  and hippo signaling pathways 46 ; and inactivating mutations of ATRX in pheochromocytoma and paraganglioma 47 (present in 2% of the tumors). These genes, except CHEK2, encode long proteins (>1,500 amino-acids) and are expected to contain numerous passenger mutations, complicating the identification of low-prevalence cancerassociated mutations using recurrence-based methods.
Additionally, the combination of the results of our analysis with those of MutSig2CV allowed us to prioritize the study of mutated genes in colon adenocarcinoma, where the number of significant genes according to MutSig2CV is too large (n = 1,698 genes, q-value < 0.15) ( Supplementary Fig. 16 ). In particular, our analysis highlighted ARHGAP5 and ARFGEF1 as previously unreported putative driver genes of tumor progression in this cancer type.
Truncating mutations of ADAMTS12 in lung adenocarcinoma (LUAD) are associated to poor survival in humans and increased tumor susceptibility in mice
Using TCGA survival data we found that, among the previously unreported cancerassociated genes, inactivating mutations of ADAMTS12 were associated with poor survival (Fig. 3a ). ADAMTS12 is a metalloproteinase with thrombospondin motif that can block the activation of the Ras-MAPK signaling pathway 43 . Immunodeficient mice injected with A549 lung adenocarcinoma cells overexpressing ADAMTS12 had a deficiency of tumor growth in comparison with tumors formed from parental A549 cells 43 .
The ADAMTS12 gene is in chromosomal arm 5p, which is entirely amplified in over 60% of lung adenocarcinoma tumors 48 . It has been suggested that the TERT gene, coding for the telomerase catalytic subunit, may be the target of this amplification 48 . Consistent with the suggested anti-tumorgenic properties of ADAMTS12, we observed that LUAD patients with chromosome 5p amplification and unaltered ADAMTS12 gene have better overall survival than those without chromosome 5p amplification (Fig. 3a , median overall survival 4.2 years versus 3.4 years respectively, Kaplan-Meier p-value = 0.05). To the contrary, patients with chromosome 5p amplification and truncating mutations in ADAMTS12 have a reduced survival with respect to patients that harbor the amplification without mutations in ADAMTS12 (Fig. 3a , median overall survival 2.4 years, Kaplan-Meier p-value = 0.015).
Additionally, truncating mutations in ADAMTS12 tend to co-occur with chromosome 5p amplification ( Fig. 3a , one-tailed Fisher's exact test p-value = 2·10 -3 ).
To validate ADAMTS12 inactivation as a driver of progression in lung carcinoma, we investigated the effect of silencing ADAMTS12 in the lung carcinoma cell line LL/2-luc-M38 using a shRNA plasmid. In vitro proliferation and invasion assays revealed a significant increase in the proliferative and invasive potential of the cells that were transfected with the shRNA plasmid compared to the control cells (Figs. 3b, c, Mann-Whitney U-test p-value < 10 -3 in both assays).
In addition to these in vitro studies, we assessed the effect of ADAMTS12 inactivation in vivo. To that end, we generated ADAMTS12 -/mice as previously described 49 and treated ADAMTS12 knockout and control mice with urethane (ethyl carbamate), a carcinogen that typically induces lung adenomas after several months of treatment 50, 51 . After 20 weeks of treatment, ADAMTS12 knockout mice showed a 5-fold enrichment on the number of lung tumors compared to control mice (Fig. 3d , Mann-Whitney U-test p-value = 3·10 -5 ). The enrichment in the number of tumors was still significant after disaggregating tumors by their size ( Supplementary Fig. 17 ). We did not find a significant difference between the observed tumor size in control and ADAMTS12 knockout mice. Immunohistochemistry staining of tumor sections from these mice revealed some level of expression of ADAMTS12 in the region surrounding the adenoma, but not in the highly-proliferative Ki-67 + cells ( Supplementary Fig. 18 ). A similar pattern of ADAMTS12 expression has been observed in human colon adenocarcinoma 52 . Taken together our results suggest ADAMTS12 has a tumor suppressor role in lung cancer, consistently with the results of our computational analysis.
Discussion
To identify which somatic mutations are relevant to the progression of tumors, most genomic analyses focus on the recurrence of mutations and define candidate cancerassociated genes as those mutated at a higher frequency than expected under a modeled local neutral mutation rate. This definition has proven to be particularly powerful for commonly mutated genes. However, it is limiting for low prevalence mutations or tumors with a higher mutation burden. Here, we have adopted an alternative definition for candidate cancer-associated gene based on the assumption that mutations in these genes are accompanied by consistent global expression patterns in the tumor. Remarkably, these two fundamentally different definitions are in practice highly consistent with each other, as we find that most mutations occurring at a high frequency compared to the local neutral mutation rate are associated with consistent global mRNA expression patterns in the tumor.
As expected, there are numerous exceptions to this rule and utilizing our approach we are able to identify multiple candidate cancer genes that remained elusive to other methods.
One example of such elusive cancer-associated mutations are truncating mutations of the PEST domain of NOTCH2 occurring in breast invasive carcinoma 40 . These rare events are easily masked by the large number of passenger mutations that this long gene accumulates.
However, we find these alterations are consistently accompanied by global changes in the expression profile of the tumor. Although they affect a small fraction of all breast cancer patients, the availability of pharmacological inhibitors of the Notch signaling pathway makes them a promising therapeutic target for the treatment of these patients 53 . Among the less studied, elusive candidate cancer-associated mutations identified with our approach, we have studied the inactivating mutations of ADAMTS12 occurring in lung adenocarcinoma. We have provided evidence of the tumor suppressor role of ADAMTS12 in this cancer type both in vitro and in vivo. Specifically, our experiments reveal that lung carcinoma LL/2-luc-M38 cells display a higher proliferative and invasive potential in vitro when transfected with an ADAMTS12 shRNA. Additionally, we have shown that mice treated with urethane have a several fold increase in the susceptibility to develop lung adenomas when ADAMTS12 is knocked out. These results are consistent with the observation that patients of lung adenocarcinoma with tumors harboring truncating mutations of ADAMTS12 have poor survival. Our work demonstrates that the combination of recurrence-based methods with integrative approaches as we describe here can be a valuable tool to systematically identify potentially actionable, low-prevalence mutations that escape standard methods of detection.
Methods
Sample collection and preprocessing
We collected gene expression levels and somatic mutation data of 12 tumor types from the TCGA repository (http://cancergenome.nih.gov/) (Table 1 and Supplementary Table 4 ).
We only considered patients for which both types of data were available. RNA-seq expression levels were retrieved in RSEM format 54 and estimated relative abundances ( ) were transformed according to the formula = log 2 (1 + 10 6 · ) for each gene. Curated somatic mutations were retrieved from the Broad Institute TCGA GDAC Firehose Portal (http://gdac.broadinstitute.org/). Gene names were adapted to comply with those in the NCBI Entrez ID database as of July 7, 2015.
Topological representations
We used the algorithm Mapper 28 , implemented in the Ayasdi software (https://www.ayasdi.com/platform/), to build topological representations of the RNA-seq data of each cancer cohort. Mapper builds upon any dimensional reduction algorithm (also known as "filter function") to produce a new low-dimensional network representation on which local relationships are preserved. To that end, Mapper covers the low dimensional representation with overlapping bins and performs single-linkage clustering of the points in the high-dimensional space. The number of bins and their overlap are specified by the "resolution" and "gain" parameters respectively. The number of clusters in each bin is determined by the method described in Singh et al. 28 . A low-dimensional network is then built by assigning a node to each cluster, and if a sample appears in two nodes they are connected by an edge. A more detailed description of the Mapper algorithm for biologists can be found in the Methods section and Supplementary Note of Rizvi et al. 25 .
The output of Mapper is sensitive to several algorithmic choices. In our application, the following choices were made: -Metric. We used Pearson's correlation distance using the top 4,500 genes with highest variance as a measure of the similarity among the expression profile of tumors. We did not observed substantial differences between using Pearson's and Spearman's correlation distance in our analyses. We therefore used Pearson's correlation distance given its reduced computation time in large datasets. -"Resolution" and "gain" parameters. We covered the low-dimensional representation with overlapping squared bins. We scanned across the entire "resolution" and "gain" parameter space of the cover, as described in the paragraph "Parameter scan and selection", obtaining stable results.
Statistical analysis
We used the notions of topological association introduced in Rizvi et al. 25 to identify features associated to localized regions of a phenotypic space. Our approach is closely related to the Laplacian score of He, Cai, and Niyogi 55, 56 , and complementary to other statistical methods for network analysis 57 . In our case, the features that we tested were the somatic mutations in the tumor cohort, and the phenotypic space was the expression space of the tumor cohort. More specifically, for each mutated gene in the cohort, we defined the following score:
where Γ denotes the set of nodes in the topological representation, its adjacency matrix, the number of nodes in the representation, and ( ) the average frequency of non-synonymous mutations of for the samples in node . The score ( ) is therefore a sum over the edges of the network, where the contribution of each edge is proportional to the product of the fraction of tumors that harbor the mutated gene in each of the two nodes connected by the edge. To be able to compare the score of mutated genes with different prevalence, we introduced a permutation test for each gene. A null distribution was built for ( ) by randomly permuting the patient id's in the exome data and a p-value was assigned to the score of each gene according to its null distribution. We performed 10 4 permutations to build the null distribution of each gene. We controlled the false discovery rate (FDR) using the Benjamini-Hochberg (BH) procedure 58 . To avoid too large corrections due to multiple hypothesis testing, we only considered mutated genes with a prevalence in the cohort above a given threshold. The thresholds used in each cohort are summarized in Supplementary Table 4 . In addition, we limited the number of genes in each analysis to the 350 genes with highest ratio between non-synonymous and total number of mutations. These thresholds were empirically determined for each cohort by looking at the size of the BH correction that resulted at different choices of the thresholds. For some cancer types, avoiding a large BH correction required relatively stringent thresholds ( Supplementary Table 4 ), possibly reflecting noisier expression networks, e.g. due to differences in tumor purity among patients.
Parameter scan and selection
To optimize the sensitivity of our approach at a fixed false discovery rate and control for the stability of the results against parameter choices, we generated 49 topological representations for the expression data of each tumor type by scanning over the parameter space of the Mapper algorithm. The resolution parameter was taken in the range 10 to 80, in intervals of 10, and the gain parameter 1.5-8.5, in intervals of 1. For each topological network, the statistical analysis performed in the previous paragraph was performed independently. We then selected a finer region in the parameter space for each cohort based on the following criteria:
-A large number of mutated genes with a significant score (q-value < 0.15) at a fixed FDR.
-Absence of significant spurious correlations and batch effects (as described in next paragraph).
For each selected region in the parameter space, we performed a finer scan across the resolution and gain parameters, taking intervals of 5 and 0.5 respectively.
Control of spurious associations with expression
Hypermutated tumors often have a distinctive expression signature. In those cases, some localized regions of the expression space will consist of tumors with a higher mutation rate.
Those localized regions will harbor an accumulation of passenger mutations that may confound our approach. To control for associations between global expression patterns and the tumor mutation rate, we assessed the localization of the mutational tumor burden on the topological representations using the same approach as described in the paragraph "Statistical analysis", where is now the average frequency of somatic mutations for the samples in node . If the localization of the mutational burden was significant (p-value < 0.05), we manually set a threshold on the mutational burden to split the cohort into hypermutated and non-hypermutated tumors. This process could have been automated, however we found it unnecessary as small changes in the threshold do not affect substantially the results. The thresholds used in each cohort are summarized in Supplementary Table 4 . We randomly subsampled mutations from each of the hypermutated tumors so that after subsampling the median mutational burden for hypermutated tumors in the cohort was equal to the median mutational burden for nonhypermutated tumors. We reassessed the significance of the localization of the mutational burden using the down sampled data. If the degree of localization of the mutational tumor burden was not significant, we continued the analysis using the down sampled mutation data. Otherwise, if the degree of localization was still significant after subsampling, we did not include the cohort in our study.
To control for associations between expression and mutation rates within the same gene, such as those due to transcription-coupled DNA repair, we assessed the similarity between the profiles of somatic mutation and mRNA expression on the topological representations.
To that end, we computed the Jensen-Shannon divergence between the expression and mutation profiles of each gene in the topological representations using the formula
where ̃( ) and ̃( ) are respectively the fraction of tumors with gene somatically mutated and the average expression of gene in the tumors associated to the -th node of the topological representation, normalized such that
The significance of ( ) was assessed for each gene independently by means of a permutation test. To that end, for each gene the labels of the samples on the mutation data were randomly permuted 2,000 times, and ( ) was computed in each permutation. A pvalue was estimated by counting the fraction of permutations that led to a value of ( ) smaller than the original value. Genes with a p-value for ( ) closed to 0 displayed a large degree of correlation between expression and mutation in the topological representation, whereas genes with a p-value for ( ) closed to 1 displayed a large degree of anti-correlation between expression and mutation in the topological representation. After adjusting for multiple hypothesis testing using Benjamini-Hochberg procedure to control the false discovery rate, we removed genes from the analysis for which the median q-value for ( ) across the parameter space of the topological representation was above 0.8, as those are potentially related to spurious anti-correlations between gene expression and mutation.
Last, to control for the presence of batch effects due to differences among mutation calling centers, we assessed the degree of localization of batches in the topological representation using the same approach as described in the paragraph "Statistical analysis", with now represents the fraction of tumors in node that were processed by a given center. We removed the contribution of batches whose degree of localization was significant (p-value < 0.05) according to this procedure.
Computational benchmarking
We generated smaller LGG datasets by randomly sampling 50, 100, 200, 300, and 400 patients from the original LGG cohort. For each of these sizes, we generated a null data set by randomly permuting the labels of the patients on the expression data. We ran the integrative topological analysis in each of these new data sets using the same parameters than in the original analysis of the LGG cohort ( Supplementary Table 4 ).
To benchmark the performance of algorithms based on a gold-standard list of cancerassociated genes, we followed the same approach as in Bertrand et al. 35 . We considered the same gold-standard list as in that reference. For each of the algorithms evaluated, we computed the precision (P), recall (R), and F1 score based the top min(15, ) significant genes (q-value < 0.15) = min(15, ) , = 15 ,
where is the total number of significant genes and the number of top min (15, ) significant genes present in the gold-standard. We run Xseq, OncodriveFML and 20/20+ with default parameters, as described in their documentation.
MutSig2CV analyses
We downloaded from the Broad Institute TCGA GDAC Firehose Portal (http://gdac.broadinstitute.org/) the MutSig2CV v3.1 analyses of each of the 12 TCGA cohorts ( Supplementary Table 4 ).
Online database
Representative topological representations and pre-computed statistics were deposited in an online database for each of the 12 tumor types considered in this study (https://rabadan.c2b2.columbia.edu/pancancer). The interface of the database allows to explore the results of the analysis interactively.
Induction of lung tumors in mice
Mouse experiments were performed following the institutional guidelines of the University of Oviedo (Comité de Ética en Experimentación Animal). Adamts12 -/mice were generated in a C57BL/6J genetic background and genotyped as in El Hour et al. 49 . Lung tumors were induced in 6-8 weeks old mice by intraperitoneal injection of 8 doses of 1 g/kg of urethane (ethyl carbamate; Sigma); second dose was given 48h after the initial one and then once a
week to reach a total of 8 doses. Mice were sacrificed 20 weeks after the first urethane injection and during this time mice were fed ad libitum. Left lungs were fixed in 4% paraformaldehyde, paraffin-embedded and sectioned every 100 m in of 10 m slices.
These were then stained with hematoxylin/eosin for morphological examination by experienced pathologists (Unidad de Histopatología Molecular en Modelos Animales de Cáncer, IUOPA). Tumors were quantified and classified according to their diameter in large (> 400 m), medium (200-400 m) and small (<200 m) tumors.
Generation of shADAMTS12 LL/2-luc-M38 cells
We used an Adamts12 Mouse shRNA Plasmid (OriGene, Locus ID: 239337) and
transfected LLC/2-luc-M38 (Caliper) cells with lipofectamine/plus (ThermoFisher Scientific) following the recommendations of manufacturer. We checked transfected cells for ADAMTS12 expression by western-blot for ADAMTS12 (Santa Cruz Biotechnology H-142) and β-actin (Sigma-Aldrich in 10% polyacrylamide gels. Immunoreactive proteins were visualized using HRP-peroxidase-labeled anti-rabbit or anti-mouse secondary antibodies and the ECL detection system (Pierce).
Proliferation assay
Cell proliferation was measured using the CellTiter 96 Non-radiactive Cell Proliferation Assay kit (Promega). LL/2-luc-M38 cells (3×10 4 /well) were seeded into 96-well plates in six replicates. Cell proliferation rates were determined on five consecutive days using the automated microtiter plate reader Power Wave WS (BioTek).
Invasion assay
In-vitro invasion potential was assessed using 24-well Matrigel-coated invasion chambers with 8 µm pore size (BD Biosciences 
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